Latanoprostene bunod
Vyzulta (latanoprostene bunod) is a small molecule pharmaceutical. Latanoprostene bunod was first approved as Vyzulta on 2017-11-02. It is known to target prostaglandin F2-alpha receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Vyzulta
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Latanoprostene bunod
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VYZULTA | Bausch Health Companies | N-207795 RX | 2017-11-02 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vyzulta | New Drug Application | 2019-05-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
215 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 10 | 6 | 11 | 14 | 8 | 46 |
| Healthy volunteers/patients | — | 26 | — | — | 4 | — | 30 | ||
| Esophagitis | D004941 | HP_0100633 | K20 | 2 | 5 | 9 | 3 | — | 19 |
| Stomach ulcer | D013276 | K25 | — | — | 11 | 1 | 1 | 13 | |
| Infections | D007239 | EFO_0000544 | — | — | 3 | 7 | 1 | 11 | |
| Heartburn | D006356 | R12 | 2 | 1 | 4 | 2 | — | 9 | |
| Peptic ulcer | D010437 | HP_0004398 | K27 | — | — | 3 | 4 | 1 | 8 |
| Laryngopharyngeal reflux | D057045 | EFO_1001355 | 1 | — | — | 3 | 3 | 7 | |
| Peptic esophagitis | D004942 | EFO_1001095 | — | 1 | 5 | 1 | — | 7 | |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | 2 | 2 | — | 4 |
Show 27 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Duodenal ulcer | D004381 | EFO_0004607 | K26 | — | — | 10 | — | 2 | 12 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | 1 | — | — | 3 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | 1 | — | — | 3 |
| Gout | D006073 | EFO_0004274 | M10 | — | 1 | 1 | — | — | 2 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | 1 | — | — | 1 |
| Lymphoma | D008223 | C85.9 | — | — | 1 | — | — | 1 | |
| Human experimentation | D006805 | — | — | 1 | — | — | 1 | ||
| Helicobacter infections | D016481 | EFO_1000961 | — | — | 1 | — | — | 1 | |
| Idiopathic pulmonary fibrosis | D054990 | J84.112 | — | — | 1 | — | — | 1 | |
| Respiratory tract infections | D012141 | J06.9 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | — | — | — | 1 | |
| Uterine neoplasms | D014594 | EFO_0003859 | C55 | — | 1 | — | — | — | 1 |
| Uterine cervical neoplasms | D002583 | — | 1 | — | — | — | 1 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | — | 1 |
| Avulsion fractures | D000071562 | 1 | 1 | — | — | — | 1 | ||
| Appendiceal neoplasms | D001063 | EFO_0003880 | C18.1 | — | 1 | — | — | — | 1 |
| Pseudomyxoma peritonei | D011553 | EFO_0007456 | — | 1 | — | — | — | 1 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 1 | — | — | — | 1 | |
| Deglutition disorders | D003680 | HP_0002015 | R13.1 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Homeostasis | D006706 | 1 | — | — | — | — | 1 | ||
| Biological availability | D001682 | 1 | — | — | — | — | 1 | ||
| Mouth neoplasms | D009062 | EFO_0003868 | C06.9 | 1 | — | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aortic valve disease | D000082862 | — | — | — | — | 1 | 1 | ||
| Coronary artery disease | D003324 | I25.1 | — | — | — | — | 1 | 1 | |
| Calcium metabolism disorders | D002128 | EFO_0005769 | E83.5 | — | — | — | — | 1 | 1 |
| Glomerulonephritis | D005921 | N05 | — | — | — | — | 1 | 1 | |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | — | — | — | 1 | 1 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | — | — | — | 1 | 1 |
| Neuroendocrine carcinoma | D018278 | — | — | — | — | 1 | 1 | ||
| Head and neck neoplasms | D006258 | — | — | — | — | 1 | 1 | ||
| Oropharyngeal neoplasms | D009959 | — | — | — | — | 1 | 1 | ||
| Peptic ulcer hemorrhage | D010438 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LATANOPROSTENE BUNOD |
| INN | latanoprostene bunod |
| Description | Latanoprostene bunod is a prostanoid. |
| Classification | Small molecule |
| Drug class | nitrogen oxide (eg., nitrxyl and nitric oxide) donors; prostaglandins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1)OCCCCO[N+](=O)[O-] |
Identifiers
| PDB | — |
| CAS-ID | 860005-21-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2364612 |
| ChEBI ID | — |
| PubChem CID | 11156438 |
| DrugBank | DB11660 |
| UNII ID | I6393O0922 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PTGFR
PTGFR
Organism
Homo sapiens
Gene name
PTGFR
Gene synonyms
NCBI Gene ID
Protein name
prostaglandin F2-alpha receptor
Protein synonyms
FP prostanoid receptor, PGF receptor, PGF2 alpha receptor, prostaglandin receptor (2-alpha), Prostanoid FP receptor
Uniprot ID
Mouse ortholog
Ptgfr (19220)
prostaglandin F2-alpha receptor (P43117)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 172 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
63,130 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more